Kaposi sarcoma: No longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm3 at presentation

Clinical and Experimental Dermatology

Volumn 39, Issue 1, 2014, Pages 7-12

  Daly, M L ^a   Fogo, A ^a   McDonald, C ^a   Morris Jones, R ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RITUXIMAB; THALIDOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPOSI SARCOMA; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME; VIRUS LOAD;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; VIRAL LOAD; YOUNG ADULT;

EID: 84890558259     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12163     Document Type: Article

References (25)

1. Uldrick TS, Whitby D,. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett 2011; 305: 150-62.
2. Martin JN, Ganem DE, Osmond DH, et al,. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338: 948-54.
3. Smith NA, Sabin CA, Gopal R, et al,. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis 1999; 180: 600-6.
4. Martro E, Esteve A, Schulz TF, et al,. Risk factors for human herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. Int J Cancer 2007; 120: 1129-35.
5. Gessain A, Mauclere P, van Beveren M, et al,. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer 1999; 81: 189-92.
6. Gutierrez-Ortega P, Hierro-Orozco S, Sanchez-Cisneros R, Montano LF,. Kaposi's sarcoma in a 6-day-old infant with human immunodeficiency virus. Arch Dermatol 1989; 125: 432-3.
7. Dodd RY,. Human herpesvirus-8: what (not) to do? Transfusion 2005; 45: 463-5.
8. Bezold G, Messer G, Peter R, et al,. Quantitation of human herpes virus 8 DNA in paraffin-embedded biopsies of HIV-associated and classical Kaposi's sarcoma by PCR. J Cutan Pathol 2001; 28: 127-30.
9. Hong YK, Foreman K, Shin JW, et al,. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36: 683-5.
10. Wang HW, Trotter MW, Lagos D, et al,. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36: 687-93.
11. Bihl F, Narayan M, Chisholm JV III, et al,. Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes. J Virol 2007; 81: 4904-8.
12. Pellett PE, Wright DJ, Engels EA, et al,. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 2003; 43: 1260-8.
13. Robey RC, Lagos D, Gratrix F, et al,. The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens. PLoS One 2009; 4: e5890.
14. Lambert M, Gannage M, Karras A, et al,. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood 2006; 108: 3871-80.
15. Bower M, Collins S, Cottrill C, et al,. British HIV Association guidelines for HIV-associated malignancies. HIV Med 2008; 9: 336-88.
16. Sunil M, Reid E, Lechowicz MJ,. Update on HHV-8-associated malignancies. Curr Infect Dis Rep 2010; 12: 147-54.
17. Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM,. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol 2005; 23: 1253-60.
18. Chan J, Kravcik S, Angel JB,. Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia. J Acquir Immune Defic Syndr 1999; 22: 209-10.
19. Krown SE, Lee JY, Dittmer DP,. More on HIV-associated Kaposi's sarcoma. N Engl J Med 2008; 358: 535-6; author reply 6.
20. Maurer T, Ponte M, Leslie K,. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357: 1352-3.
21. Stebbing J, Powles T, Bower M,. AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count. AIDS 2008; 22: 551-2.
22. Crum-Cianflone NF, Hullsiek KH, Ganesan A, et al,. Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic? AIDS 2010; 24: 2881-3.
23. Guihot A, Dupin N, Marcelin AG, et al,. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194: 1078-88.
24. Harrington W Jr, Sieczkowski L, Sosa C, et al,. Activation of HHV-8 by HIV-1 tat. Lancet 1997; 349: 774-5.
25. Nasti G, Martellotta F, Berretta M, et al,. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98: 2440-6.